Pyxis Oncology is trading 5.4% up now at $4.10 after announcing a September 9, 2026, webcast at 7:30 a.m. ET presenting updated Phase 1 MICVO data in recurrent/metastatic head and neck cancer.

  • Thomas Civik was appointed permanent CEO and chairman on September 8, strengthening leadership ahead of key clinical updates.
  • The catalyst is company-specific, although broader markets are modestly weaker.